BR9507657A - Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte - Google Patents

Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte

Info

Publication number
BR9507657A
BR9507657A BR9507657A BR9507657A BR9507657A BR 9507657 A BR9507657 A BR 9507657A BR 9507657 A BR9507657 A BR 9507657A BR 9507657 A BR9507657 A BR 9507657A BR 9507657 A BR9507657 A BR 9507657A
Authority
BR
Brazil
Prior art keywords
papillomavirus
virus
particles
antibodies
isolated
Prior art date
Application number
BR9507657A
Other languages
English (en)
Inventor
Kathrin U Jansen
James C Cook Iii
Hugh A George
Kathryn J Hofmann
Joseph G Joyce
Ernest Dale Lehman
Henry Z Markus
Mark Rosolowsky
Loren D Schultz
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9507657A publication Critical patent/BR9507657A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR9507657A 1994-05-16 1995-05-15 Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte BR9507657A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24279494A 1994-05-16 1994-05-16
PCT/US1995/006006 WO1995031532A1 (en) 1994-05-16 1995-05-15 Papillomavirus vaccines

Publications (1)

Publication Number Publication Date
BR9507657A true BR9507657A (pt) 1997-09-09

Family

ID=22916213

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507657A BR9507657A (pt) 1994-05-16 1995-05-15 Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte

Country Status (24)

Country Link
EP (1) EP0757717B1 (pt)
JP (1) JP3863559B2 (pt)
CN (1) CN1152935A (pt)
AT (1) ATE328068T1 (pt)
AU (1) AU693203B2 (pt)
BG (1) BG100974A (pt)
BR (1) BR9507657A (pt)
CA (1) CA2189882C (pt)
CZ (1) CZ336696A3 (pt)
DE (1) DE69535018T2 (pt)
DK (1) DK0757717T3 (pt)
ES (1) ES2264126T3 (pt)
FI (1) FI119815B (pt)
HU (1) HUT76354A (pt)
MX (1) MXPA96005662A (pt)
NO (1) NO322133B1 (pt)
NZ (1) NZ285941A (pt)
PL (1) PL183781B1 (pt)
PT (1) PT757717E (pt)
RO (1) RO117541B1 (pt)
RU (1) RU2206608C2 (pt)
SI (1) SI0757717T1 (pt)
SK (1) SK147696A3 (pt)
WO (1) WO1995031532A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
HUT77337A (hu) * 1994-09-22 1998-03-30 Merck & Co. Inc. Humán papillomavírus 6A-típusát kódoló DNS
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
PT1105466E (pt) 1998-08-14 2006-07-31 Merck & Co Inc Processo para a purificacao de particulas tipo virus do papilomavirus humano
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
AU764138B2 (en) * 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
MXPA04010603A (es) 2002-04-30 2004-12-13 Oncolytics Biotech Inc Metodos mejorados de purificacion viral.
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
ES2634323T3 (es) * 2004-09-30 2017-09-27 Bayer Healthcare Llc Dispositivos y procedimientos para la fabricación continua integrada de moléculas biológicas
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
JP5476544B2 (ja) 2006-09-29 2014-04-23 タケダ ワクチン，インコーポレイテッド ノロウイルスワクチン製剤
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
WO2008113011A2 (en) * 2007-03-14 2008-09-18 Ligocyte Pharmaceuticals, Inc. Virus like particle purification
WO2009001867A1 (ja) * 2007-06-26 2008-12-31 Japan Health Sciences Foundation 高リスク群ヒトパピローマウイルスに対する交差性中和抗体を誘導するワクチン抗原
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
MY182347A (en) * 2007-11-23 2021-01-20 Shanghai Zerun Biotechnology Co Ltd Genes encoding major capsid protein l1 of human papilloma virus and use of the same
EP3382011A1 (en) 2008-08-08 2018-10-03 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
CN102234661A (zh) * 2010-04-23 2011-11-09 北京生物制品研究所 人***瘤病毒类病毒颗粒的制备方法和外源蛋白表达盒、表达***
ES2630012T3 (es) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
TW201307561A (zh) * 2011-04-29 2013-02-16 腫瘤防治生化科技公司 使用凝膠滲透層析法純化病毒之方法
SG10201605644WA (en) 2011-07-11 2016-09-29 Takeda Vaccines Inc Parenteral norovirus vaccine formulations
US9771397B2 (en) * 2011-12-01 2017-09-26 University Of Cape Town HPV chimaeric particle
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv18 l1蛋白的方法
CN107916234A (zh) * 2012-03-28 2018-04-17 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv6 l1蛋白的方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv52 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv58 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达***产生hpv31 l1蛋白的方法
CN104673760B (zh) * 2013-11-29 2018-01-02 南京赛威信生物医药有限公司 一种原核细胞表达类病毒颗粒的纯化方法
RU2546241C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 16
RU2546242C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 18
RU2546240C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 56
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
EA201790944A1 (ru) * 2014-12-26 2017-11-30 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
KR20200000497A (ko) * 2015-09-04 2020-01-02 인벤트프라이즈 엘엘씨 Vlp 안정화된 백신 조성물
RU2676160C1 (ru) * 2018-02-14 2018-12-26 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей Hansenula polymorpha - продуцент главного капсидного белка L1 вируса папилломы человека типа 11
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
CN116426396B (zh) * 2023-06-09 2023-09-01 内蒙古工业大学 一株耐硫酸铵酿酒酵母及其筛选方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
CA2113712C (en) * 1991-07-19 2007-06-12 Ian Frazer Papilloma virus vaccine
EP0647140B1 (en) * 1992-06-25 2007-12-12 Georgetown University Papillomavirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product

Also Published As

Publication number Publication date
NZ285941A (en) 1998-05-27
DK0757717T3 (da) 2006-09-25
FI964592A0 (fi) 1996-11-15
MXPA96005662A (es) 2004-08-19
CZ336696A3 (en) 1997-07-16
FI964592A (fi) 1996-11-15
HU9603155D0 (en) 1997-01-28
CN1152935A (zh) 1997-06-25
JP3863559B2 (ja) 2006-12-27
NO964862D0 (no) 1996-11-15
PL317234A1 (en) 1997-03-17
EP0757717B1 (en) 2006-05-31
HUT76354A (en) 1997-08-28
CA2189882C (en) 2005-09-20
EP0757717A1 (en) 1997-02-12
JPH10500847A (ja) 1998-01-27
CA2189882A1 (en) 1995-11-23
FI119815B (fi) 2009-03-31
SK147696A3 (en) 1997-08-06
ES2264126T3 (es) 2006-12-16
RU2206608C2 (ru) 2003-06-20
PL183781B1 (pl) 2002-07-31
DE69535018D1 (de) 2006-07-06
AU2549595A (en) 1995-12-05
DE69535018T2 (de) 2007-02-15
BG100974A (en) 1998-04-30
ATE328068T1 (de) 2006-06-15
NO964862L (no) 1997-01-16
PT757717E (pt) 2006-09-29
RO117541B1 (ro) 2002-04-30
AU693203B2 (en) 1998-06-25
EP0757717A4 (en) 1998-04-15
SI0757717T1 (sl) 2006-08-31
NO322133B1 (no) 2006-08-21
WO1995031532A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
BR9507657A (pt) Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
DE69130262T2 (de) Isolierte virale proteine als cytokinantagonisten
DK0809700T3 (da) Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
HU9202645D0 (en) Synthetic antigenes applicables for detecting antibodies of hepatitis c virus
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
DE69232906T2 (de) Detektion des Hepatis-C Virus.
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
AR004464A1 (es) Un metodo para producir una proteina de capside de papilomavirus
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
DE69011122D1 (de) Rubella-e1 und c peptide.
DE69328488T2 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
DE69836226D1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]